Intercept Pharmaceuticals
Intercept’s NASH liver fibrosis drug shows promise at Phase 3
February 20, 2019Research and Development Intercept Pharmaceuticals, nash, non-alcoholic steatohepatitis, ocaliva, pharma
Intercept Pharmaceuticals has publicised promising new data on the efficacy of Ocaliva (obeticholic acid) in the treatment of liver fibrosis …
19 deaths from liver drug causes Intercept shares to tumble
September 22, 2017Medical Communications, Sales and Marketing Intercept Pharmaceuticals, Ocliva, biotech, drugs, pharma, pharmaceutical
Intercept Pharmaceuticals had sparked major concerns over its drug, Ocaliva, after it revealed that 10 people had died as a …
NICE approves first biliary cholangitis drug in 20 years
March 2, 2017Sales and Marketing Intercept Pharmaceuticals, intercept, liver disease, ocaliva, primary biliary cholangitis
Intercept Pharmaceuticals has announced that Ocaliva (obeticholic acid) has been approved by the National Institute for Health and Care Excellence …
US panel supports accelerated approval for Intercept’s trial drug for rare liver condition
April 8, 2016Medical Communications, Research and Development, Sales and Marketing Intercept Pharmaceuticals, PDUFA, US FDA, liver disorder, rare disease
Intercept Pharmaceuticals (Nasdaq: ICPT) said a US Food and Drug Administration (FDA) advisory committee has recommended accelerated approval for its …
Latest content
Five Facts about cardiovascular disease
August 9, 2026
Artificial hearts: a century of innovation
August 9, 2026
